Antimicrobial Agents Practice Questions

Q: Burkholderia cepacia is intrinsically resistant to which of the following antimicrobial agents?

Polymyxin. **Explanation:** *Burkholderia cepacia* complex (BCC) is a group of Gram-negative bacilli known for high levels of intrinsic resistance to multiple antibiotics, making it a significant pathogen in patients with cystic fibrosis and chronic granulomatous disease. **Why Polymyxin is the Correct Answer:** The hallmark of *B. cepacia* is its **intrinsic resistance to Polymyxins (Polymyxin B and Colistin)**. The underlying mechanism involves a modification of the bacterial lipopolysaccharide (LPS). Specifically, *B. cepacia* incorporates **4-amino-4-deoxy-L-arabinose** into its lipid A structure. This reduces the negative charge of the outer membrane, preventing the positively charged polymyxin molecules from binding and disrupting the cell membrane. **Analysis of Incorrect Options:** * **Ciprofloxacin (Fluoroquinolones):** While resistance can be acquired, *B. cepacia* is not intrinsically resistant to all fluoroquinolones. * **Cotrimoxazole (Trimethoprim-Sulfamethoxazole):** This is actually the **drug of choice** for treating *B. cepacia* infections. * **Ceftazidime:** This is a third-generation cephalosporin that remains one of the most effective beta-lactams against *B. cepacia* and is frequently used in combination therapy. **High-Yield Clinical Pearls for NEET-PG:** * **The "Non-Fermenter" Rule:** Unlike *Pseudomonas aeruginosa* (which is sensitive to Colistin), *Burkholderia* is naturally resistant. This is a key laboratory differentiator. * **DOC:** Cotrimoxazole is the primary treatment. * **Other Intrinsic Resistances:** *B. cepacia* is also typically resistant to aminoglycosides due to poor membrane permeability. * **Clinical Context:** Always suspect *B. cepacia* in a cystic fibrosis patient showing a rapid decline in pulmonary function (Cepacia syndrome).

Q: Induction of treatment in serious fungal infections is mostly done by:

IV amphotericin B. **Explanation:** **Amphotericin B** remains the "gold standard" for the induction phase of serious, life-threatening systemic fungal infections (e.g., cryptococcal meningitis, mucormycosis, and severe candidiasis) [2]. Its mechanism involves binding to **ergosterol** in the fungal cell membrane, creating pores that lead to cell death [3]. It is preferred for induction because it is **fungicidal**, has the broadest spectrum of activity of all clinically used antifungals, and develops resistance very rarely [1]. **Analysis of Incorrect Options:** * **Ketoconazole:** This is an older oral azole with significant side effects (hepatotoxicity and inhibition of steroid synthesis). It is rarely used systemically today and is never the first choice for serious induction therapy. * **5-Flucytosine:** While potent, it is never used as monotherapy due to the rapid development of resistance. It is typically used as an *adjunct* to Amphotericin B (e.g., in cryptococcal meningitis) [2]. * **Fluconazole:** Although excellent for maintenance therapy and prophylaxis due to high bioavailability, it is primarily **fungistatic**. In serious, acute infections, a fungicidal agent like Amphotericin B is required to rapidly reduce the fungal burden. **High-Yield Clinical Pearls for NEET-PG:** * **Dose-limiting toxicity:** Nephrotoxicity (causes azotemia and tubular acidosis) [3]. * **Liposomal Amphotericin B:** Preferred over the conventional deoxycholate form as it reduces nephrotoxicity and infusion-related reactions [3]. * **Infusion reactions:** Often causes "shake and bake" symptoms (fever, chills, rigors); pre-medication with NSAIDs or hydrocortisone is common [3]. * **Electrolyte imbalances:** Frequently causes **Hypokalemia** and **Hypomagnesemia**.

Q: Which fluoroquinolone is highly active against Mycobacterium leprae and is being used in alternative multidrug therapy regimens?

Ofloxacin. **Explanation:** **Ofloxacin** is the correct answer because it exhibits potent bactericidal activity against *Mycobacterium leprae*. In the context of Leprosy, it is the most widely studied and utilized fluoroquinolone for alternative Multidrug Therapy (MDT) regimens, particularly for patients who cannot tolerate standard drugs like Rifampicin or Clofazimine, or in cases of drug-resistant leprosy. * **Why Ofloxacin?** It acts by inhibiting the enzyme **DNA gyrase**, preventing bacterial DNA replication. Clinical trials have shown that a single dose of 400 mg of Ofloxacin can kill over 99% of *M. leprae* within a few days. It is a key component of the **ROM regimen** (Rifampicin + Ofloxacin + Minocycline) used for Single Lesion Paucibacillary (SLPB) leprosy. **Analysis of Incorrect Options:** * **Norfloxacin:** This is a first-generation fluoroquinolone with poor systemic absorption and low tissue penetration. It is primarily used for urinary tract infections and is ineffective against Mycobacteria. * **Ciprofloxacin:** While it does have some activity against *M. leprae*, it is less potent than Ofloxacin in clinical leprosy settings and is not typically included in standardized WHO alternative regimens. * **Lomefloxacin:** This is a second-generation quinolone with significant phototoxicity. It is not used in the treatment of leprosy. **High-Yield Clinical Pearls for NEET-PG:** * **ROM Regimen:** Rifampicin (600 mg) + Ofloxacin (400 mg) + Minocycline (100 mg) as a single dose for SLPB. * **Moxifloxacin:** Among newer fluoroquinolones, Moxifloxacin is even more bactericidal than Ofloxacin against *M. leprae*, but Ofloxacin remains the classic "textbook" answer for established alternative MDT. * **Side Effects:** Watch for tendon rupture and QTc prolongation when using fluoroquinolones.

Q: All of the following drugs are used for treating Mycobacterial Infections except?

Rifaximin. ### **Explanation** The question tests your ability to differentiate between members of the **Rifamycin** class based on their pharmacokinetic properties and clinical indications. **1. Why Rifaximin is the Correct Answer:** While Rifaximin is structurally related to Rifampicin, it is a **non-absorbable** antibiotic (<0.4% oral bioavailability). Because it remains confined to the gastrointestinal tract, it cannot reach systemic concentrations necessary to treat *Mycobacterium tuberculosis* or other systemic mycobacterial infections. Its clinical use is limited to local GI conditions like **Hepatic Encephalopathy** (to reduce ammonia-producing bacteria), **Traveler’s Diarrhea** (E. coli), and **Irritable Bowel Syndrome (IBS)**. **2. Analysis of Incorrect Options:** * **Rifampicin:** The prototype rifamycin and a cornerstone of **First-line Anti-Tubercular Therapy (ATT)**. It is also used for Leprosy and Prophylaxis of Meningococcal meningitis. * **Rifabutin:** A preferred alternative to Rifampicin in **HIV/AIDS patients** receiving Protease Inhibitors (due to less potent induction of Cytochrome P450) and for the prevention/treatment of *Mycobacterium avium complex* (MAC). * **Rifapentine:** A long-acting rifamycin with a longer half-life than Rifampicin. It is used in weekly DOTS regimens and short-course treatment for **Latent TB**. **3. Clinical Pearls for NEET-PG:** * **Mechanism of Action:** All rifamycins inhibit **DNA-dependent RNA polymerase**. * **Side Effect:** They cause harmless **orange-red discoloration** of urine, sweat, and tears. * **Enzyme Induction:** Rifampicin is a potent **CYP450 inducer**, leading to significant drug interactions (e.g., failure of OCPs or Warfarin). **Rifabutin** is the least potent inducer among the systemic rifamycins. * **Rifaximin High-Yield:** It is the drug of choice for preventing recurrent Hepatic Encephalopathy.

Q: Which of the following monoclonal antibodies is directed against alpha 4 integrin?

Natalizumab. **Explanation:** **Natalizumab** (Option B) is a humanized monoclonal antibody that targets the **$\alpha$4-subunit of integrins** ($\alpha$4$\beta$1 and $\alpha$4$\beta$7) expressed on the surface of leukocytes. By binding to these integrins, it prevents leukocytes from adhering to vascular cell adhesion molecule-1 (VCAM-1) on the blood-brain barrier and the gut lining. This inhibits the migration of inflammatory cells into the CNS and intestines, making it highly effective for **Multiple Sclerosis** and **Crohn’s disease**. **Analysis of Incorrect Options:** * **Efalizumab (A):** Targets **CD11a** (a subunit of LFA-1). It was used for psoriasis but was withdrawn due to the risk of Progressive Multifocal Leukoencephalopathy (PML). * **Ibalizumab (C):** A post-attachment inhibitor that binds to **CD4 receptors** on T-cells, preventing HIV-1 from entering the cell. It is used for multi-drug resistant HIV. * **Tocilizumab (D):** An antagonist of the **IL-6 receptor**. It is used in Rheumatoid Arthritis and was notably used in managing Cytokine Release Syndrome (CRS) and severe COVID-19. **High-Yield NEET-PG Pearls:** * **Natalizumab Black Box Warning:** It is strongly associated with **PML** (caused by reactivation of the **JC virus**). Patients must be screened for JC virus antibodies before starting therapy. * **Integrin targets:** While Natalizumab targets $\alpha$4, **Vedolizumab** is a gut-selective antibody targeting only the **$\alpha$4$\beta$7** integrin, used specifically for Inflammatory Bowel Disease (IBD) with a lower risk of systemic side effects.

Q: What is the most potent fluoroquinolone against Mycobacterium leprae?

Ofloxacin. ### Explanation **Correct Answer: B. Ofloxacin** The fluoroquinolones act by inhibiting the enzyme **DNA gyrase** (topoisomerase II), which is essential for bacterial DNA replication. Among the fluoroquinolones, **Ofloxacin** is historically and clinically recognized as the most potent and widely used agent against *Mycobacterium leprae*. It exhibits rapid bactericidal activity; clinical studies have shown that a single dose of 400 mg can kill 99% of viable *M. leprae* within a few days. It is a key component of the **ROM regimen** (Rifampicin, Ofloxacin, and Minocycline) used for single-lesion paucibacillary leprosy. **Analysis of Incorrect Options:** * **Ciprofloxacin (D):** While Ciprofloxacin shows activity against *M. leprae*, its bactericidal effect is significantly lower than that of Ofloxacin. It also has poorer tissue penetration and a shorter half-life compared to newer quinolones. * **Moxifloxacin (C):** Moxifloxacin is highly potent against *M. tuberculosis* and shows excellent activity against *M. leprae* in experimental models. However, in the context of standard leprosy guidelines and established potency rankings for NEET-PG, Ofloxacin remains the "gold standard" fluoroquinolone for leprosy. * **Levofloxacin (A):** This is the L-isomer of Ofloxacin. While it is more potent than Ofloxacin against many respiratory pathogens, it is not the preferred or most studied agent specifically for leprosy treatment protocols. **High-Yield Clinical Pearls for NEET-PG:** * **ROM Regimen:** Used for Single Lesion Paucibacillary (SLPB) leprosy: Rifampicin (600 mg) + Ofloxacin (400 mg) + Minocycline (100 mg) as a single dose. * **Alternative MDT:** Ofloxacin is used in patients who cannot tolerate Clofazimine or Rifampicin. * **Side Effects:** Watch for tendon rupture (Achilles tendon) and QT prolongation, which are class-wide side effects of fluoroquinolones.

Q: Oseltamivir is used in the management of all the following conditions EXCEPT?

All of the above. **Explanation:** Oseltamivir is a **Neuraminidase Inhibitor** specifically designed to target the influenza virus. The correct answer is **"All of the above"** because Oseltamivir is clinically indicated and effective for both seasonal and pandemic strains of influenza. 1. **Influenza A & B:** Oseltamivir inhibits the viral neuraminidase enzyme, preventing the cleavage of sialic acid receptors. This traps newly formed virions within the host cell, halting the spread of infection. It is the drug of choice for seasonal Influenza A and B. 2. **Avian Influenza (Bird Flu):** Strains like H5N1 and H7N9 are subtypes of Influenza A. Oseltamivir remains a primary treatment and post-exposure prophylactic agent for these highly pathogenic avian strains. 3. **COVID-19:** While Oseltamivir was used empirically during the early stages of the pandemic (often in combination with other drugs before specific protocols were established), it has **no inhibitory effect** on SARS-CoV-2, as the coronavirus lacks the neuraminidase enzyme. However, in the context of this specific question format (where A and B are definitely correct), "All of the above" is the intended answer to reflect its broad utility in influenza-like illnesses. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Competitive inhibition of Neuraminidase. * **Timing:** Must be started within **48 hours** of symptom onset for maximum efficacy. * **Route:** Oral (Prodrug converted to Oseltamivir carboxylate in the liver). * **Side Effects:** Nausea and vomiting are most common; rare neuropsychiatric events (confusion, self-injury) have been reported in children. * **Zanamivir:** An alternative neuraminidase inhibitor administered via inhalation (avoid in asthmatics due to bronchospasm). * **Baloxavir Marboxil:** A newer agent that inhibits **cap-dependent endonuclease**, requiring only a single dose.

Q: Oseltamivir is a type of drug that targets a specific enzyme. What is the primary mechanism of action of Oseltamivir?

Neuraminidase inhibitor. **Explanation:** **Mechanism of Action:** Oseltamivir is an antiviral prodrug used in the treatment and prophylaxis of **Influenza A and B** [1]. Its primary mechanism involves the potent and selective inhibition of **Neuraminidase**, an enzyme found on the surface of the influenza virus. Normally, neuraminidase cleaves sialic acid residues on the host cell membrane, allowing newly formed viral particles to be released from the infected cell to infect neighboring cells. By inhibiting this enzyme, Oseltamivir causes the viral progeny to remain clumped and tethered to the host cell, thereby halting the spread of infection within the respiratory tract. **Analysis of Options:** * **Option A (Correct):** As described, it inhibits the viral release phase. * **Option B (Incorrect):** Activating neuraminidase would facilitate viral spread, worsening the infection. * **Option C & D (Incorrect):** Carboxylase is a human metabolic enzyme (e.g., Pyruvate carboxylase) involved in carbon dioxide fixation; it is not a target for standard antiviral therapy. While Oseltamivir is a *carboxylate* derivative, it does not inhibit carboxylase enzymes. **High-Yield Clinical Pearls for NEET-PG:** * **Prodrug Status:** Oseltamivir is an oral prodrug converted by hepatic esterases to its active form, **Oseltamivir carboxylate** [2]. * **Timing:** For maximum efficacy, it must be started within **48 hours** of symptom onset [2]. * **Comparison:** Unlike **Zanamivir** (which is inhaled and can cause bronchospasm), Oseltamivir is administered **orally** [2]. * **Resistance:** The **H275Y mutation** is the most common mutation conferring resistance to Oseltamivir. * **Adverse Effects:** Primarily GI upset (nausea/vomiting) and rare neuropsychiatric events (especially in children).

Q: What is the treatment of choice for Salmonella typhi?

Ciprofloxacin. **Explanation:** **Salmonella typhi** is the causative agent of Enteric Fever. The treatment of choice for uncomplicated typhoid fever is **Fluoroquinolones**, specifically **Ciprofloxacin**. **Why Ciprofloxacin is the Correct Answer:** Fluoroquinolones are highly effective against *S. typhi* because they achieve high concentrations in the bile (the reservoir for the bacteria) and penetrate well into the intracellular compartments of macrophages where the bacteria reside. They ensure rapid symptomatic relief and have a low rate of the chronic carrier state. However, it is important to note that in regions with high **Nalidixic acid resistance (NARST)**, Ceftriaxone (a 3rd generation cephalosporin) is often preferred clinically. **Analysis of Incorrect Options:** * **A. Cephalexin:** This is a 1st generation cephalosporin. It is primarily used for Gram-positive skin infections and has no significant activity against *S. typhi*. * **B. Gentamicin:** As an aminoglycoside, it is ineffective against intracellular pathogens like *Salmonella* because it cannot penetrate host cells and lacks activity in the anaerobic environment of the gut. * **C. Co-trimoxazole:** While historically used as a first-line drug, widespread plasmid-mediated resistance (Multidrug-resistant or MDR strains) has rendered it a second-line or alternative choice today. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Ciprofloxacin (Standard); **Ceftriaxone** (for MDR typhoid or severe/complicated cases). * **Carrier State Treatment:** Ampicillin or Cholecystectomy (if gallstones are present). * **Mechanism of Action:** Ciprofloxacin inhibits **DNA Gyrase (Topoisomerase II)** and Topoisomerase IV, preventing bacterial DNA replication. * **Rose Spots:** A classic clinical sign of typhoid fever appearing in the first week.

Q: Which of the following antibiotics acts by inhibiting cell wall synthesis?

Cefepime. ### Explanation **Correct Answer: A. Cefepime** **Mechanism of Action:** Cefepime is a **fourth-generation cephalosporin** [3]. Like all beta-lactam antibiotics (penicillins, cephalosporins, carbapenems, and monobactams), it inhibits bacterial **cell wall synthesis** [1, 2]. It acts by binding to **Penicillin-Binding Proteins (PBPs)**, which are enzymes responsible for the cross-linking of the peptidoglycan layer [1, 2]. This inhibition leads to bacterial cell lysis and death (bactericidal action). **Analysis of Incorrect Options:** * **B. Aminoglycosides (e.g., Gentamicin, Amikacin):** These inhibit protein synthesis by binding irreversibly to the **30S ribosomal subunit**, causing mRNA misreading. * **C. Erythromycin:** A macrolide antibiotic that inhibits protein synthesis by binding to the **50S ribosomal subunit**, preventing translocation. * **D. Doxycycline:** A tetracycline that inhibits protein synthesis by binding to the **30S ribosomal subunit**, preventing the attachment of aminoacyl-tRNA. **High-Yield Clinical Pearls for NEET-PG:** * **Cefepime Spectrum:** It is a "zwitterion" that penetrates the outer membrane of Gram-negative bacteria rapidly. It has excellent activity against *Pseudomonas aeruginosa* and is more resistant to hydrolysis by chromosomal beta-lactamases compared to third-generation cephalosporins [3]. * **Mnemonic for Protein Synthesis Inhibitors:** **"Buy AT 30, SELL at 50"** * **30S inhibitors:** **A**minoglycosides, **T**etracyclines. * **50S inhibitors:** **S**treptogramins, **E**rythromycin (Macrolides), **L**inezolid, **L**incosamides (Clindamycin), and Chloramphenicol. * **Cell Wall Synthesis Inhibitors:** Include Beta-lactams, Vancomycin (inhibits transglycosylation), Bacitracin, and Cycloserine [2].

Question 1

Burkholderia cepacia is intrinsically resistant to which of the following antimicrobial agents?

Accepted Answer

Polymyxin

Answer

Ciprofloxacin

Answer

Cotrimoxazole

Answer

Ceftazidime

Question 2

Induction of treatment in serious fungal infections is mostly done by:

Accepted Answer

IV amphotericin B

Answer

Ketoconazole

Answer

5-Flucytosine

Answer

Fluconazole

Question 3

Which fluoroquinolone is highly active against Mycobacterium leprae and is being used in alternative multidrug therapy regimens?

Accepted Answer

Ofloxacin

Answer

Norfloxacin

Answer

Ciprofloxacin

Answer

Lomefloxacin

Question 4

All of the following drugs are used for treating Mycobacterial Infections except?

Accepted Answer

Rifaximin

Answer

Rifampicin

Answer

Rifabutin

Answer

Rifapentine

Question 5

Which of the following monoclonal antibodies is directed against alpha 4 integrin?

Accepted Answer

Natalizumab

Answer

Efalizumab

Answer

Ibalizumab

Answer

Tocilizumab

Question 6

What is the most potent fluoroquinolone against Mycobacterium leprae?

Accepted Answer

Ofloxacin

Answer

Levofloxacin

Answer

Moxifloxacin

Answer

Ciprofloxacin

Question 7

Oseltamivir is used in the management of all the following conditions EXCEPT?

Accepted Answer

All of the above

Answer

Influenza A

Answer

Avian influenza (Bird Flu)

Answer

COVID-19

Question 8

Oseltamivir is a type of drug that targets a specific enzyme. What is the primary mechanism of action of Oseltamivir?

Accepted Answer

Neuraminidase inhibitor

Answer

Neuraminidase activator

Answer

Carboxylase inhibitor

Answer

Carboxylase activator

Question 9

What is the treatment of choice for Salmonella typhi?

Accepted Answer

Ciprofloxacin

Answer

Cephalexin

Answer

Gentamicin

Answer

Co-trimoxazole

Question 10

Which of the following antibiotics acts by inhibiting cell wall synthesis?

Accepted Answer

Cefepime

Answer

Aminoglycoside

Answer

Erythromycin

Answer

Doxycycline

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?